BARRX signs Japan distribution deal for ablation system
This article was originally published in Clinica
BARRX Medical is to take its HALO radiofrequency ablation system to the Japanese market after signing an exclusive distribution deal with medical product supply company Medico’s Hirata. The HALO system, which is also FDA-cleared and CE-marked, is designed to treat gastroenterological diseases by removing diseased tissue and allowing the re-growth of new, normal cells. According to Sunnyvale, California-based BARRX, the HALO system “has shown encouraging results in recent clinical trials…in eradicating early oesophageal squamous neoplasia, a precursor to oesophageal cancer”. BARRX said that Japan has one of the highest concentrations of oesophageal squamous cell cancers in the world. Financial terms of the deal were not disclosed.